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Abstract
Background: Cardiac asthma is common, but has been poorly investigated. The objective was to
compare the characteristics and outcome of cardiac asthma with that of classical congestive heart
failure (CHF) in elderly patients.
Methods: Prospective study in an 1,800-bed teaching hospital.
Results: Two hundred and twelve consecutive patients aged ≥ 65 years presenting with dyspnea
due to CHF (mean age of 82 ± 8 years) were included. Findings of cardiac echocardiography and
natriuretic peptides levels were used to confirm CHF. Cardiac asthma patients were defined as a
patient with CHF and wheezing reported by attending physician upon admission to the emergency
department. The CHF group (n = 137) and the cardiac asthma group (n = 75), differed for tobacco
use (34% vs. 59%, p < 0.05), history of chronic obstructive pulmonary disease (16% vs. 47%, p <
0.05), peripheral arterial disease (10% vs. 24%, p < 0.05). Patients with cardiac asthma had a
significantly lower pH (7.38 ± 0.08 vs. 7.43 ± 0.06, p < 0.05), and a higher PaCO2 (47 ± 15 vs. 41 ±
11 mmHg, p < 0.05) at admission. In the cardiac asthma group, patients had greater distal airway
obstruction: forced expiratory volume in 1 second of 1.09 vs. 1.33 Liter (p < 0.05), and a forced
expiratory flow at 25% to 75% of vital capacity of 0.76 vs. 0.99 Liter (p < 0.05). The in-hospital (23%
vs. 19%) and one year mortality (48% vs. 43%) rates were similar.
Conclusion: Patients with cardiac asthma represented one third of CHF in elderly patients. They
were more hypercapnic and experienced more distal airway obstruction. However, outcomes
were similar.
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Background
In Western countries, the population is getting older, and
it is projected that there will be a doubling of individuals
over the age of 65 and 80 years by 2030 [1]. It is estimated
that about 10% of the population over the age of 80 years
have heart failure [1]. Congestive heart failure (CHF) is
the leading cause of acute dyspnea in elderly patients,
with an in-hospital mortality ranging from 13 to 29 % [2-
8]. CHF presenting with wheezing is termed cardiac
asthma [9,10]. Although airflow obstruction in the setting
of cardiogenic pulmonary edema (CPE) has long been
familiar to clinicians, the mechanisms responsible for this
observation remain obscure. The elevation of pulmonary
or bronchial vascular pressure likely results in reflex bron-
choconstriction [10-13]. Other potential causes of airway
narrowing include a geometric decrease in airway size
from reduced lung volume, obstruction from intralumi-
nal edema fluid, and bronchial mucosal swelling [14-16].
Some investigators have found an increase in bronchial
responsiveness to methacholine in patients with CHF
[10,12]. However, there is little knowledge of the preva-
lence presentation, clinical characteristics and outcomes
of cardiac asthma in elderly patients.
Therefore, the objectives of this study were to 1) deter-
mine the incidence of wheezing, though to reflect the
occurrence of bronco-obstruction ("cardiac asthma"),
during CHF, and 2) compare the characteristics (clinical
and functional), and prognosis of patients with cardiac
asthma to that of classical CPE (non wheezing CPE) in
patients aged 65 years and over.
Methods
Study design and setting
A single-center prospective study was conducted between
February 2001 and September 2002, in an emergency
department (ED) of a 1,800 bed teaching urban hospital.
This work was an ancillary analysis of an epidemiological
study of acute respiratory failure in elderly patients (EPI-
DASA study) which has been previously described in
detail elsewhere [5]. In the present study, patients with
CHF were included and compared according to the pres-
ence or absence of wheezing. The study was approved by
our Institutional Review Board, and waived informed
consent was authorized because routine care of the
patient was not modified.
Selection of participants
The criteria for inclusion in the EPIDASA study were: age
≥ 65 years and acute dyspnea. In addition, one of the fol-
lowing criteria had to be fulfilled: 1) respiratory rate ≥ 25/
min; 2) PaO2 ≤ 70 mmHg; 3) PaCO2 ≥ 45 mmHg with pH
≤ 7.35; 4) peripheral oxygen saturation (SpO2) ≤ 92 %. To
be included in the present study, patient should have CHF
as defined by experts (see below). There was no exclusion
criteria in the EPIDASA study; we excluded only patients
with obvious acute bronchial asthma, as defined by
experts.
Data collection and processing
For every patient, medical care instituted by physicians in
charge included: medical history especially cardiac risk
factors, previous cardiac and respiratory diseases, physical
examination, arterial blood gas analysis (performed on a
ABL 725™, Radiometer Copenhagen, Danemark), 12 lead
electrocardiogram, and chest X-ray. Emergency treatments
and admission were decided by the emergency physician
according to normal practices and recommendations
[3,15]. Creatinine levels were measured, and creatinine
clearance was estimated with the Cockcroft formula. B-
type natriuretic peptide (BNPTriage™, Biosite, Buc,
France) and its N-terminal fraction (NT-proBNP Elecsys™
2010 analyser, Roche Diagnostics, Meylan, France) levels
were reported when available [4]. As recommended for
confirming CHF in elderly patient, a transthoracic Dop-
pler-echocardiography with emphasis on diastolic func-
tion was performed if available, and as quickly as possible
during the hospitalization. Septal E/Ea ratio was used as a
simple and reliable noninvasive surrogate for pulmonary
capillary pressure regardless of rhythm [20]. Non systolic
heart failure was defined when the ejection fraction of left
ventricule was above 50%. Pulmonary function tests
(PFTs) (performed on a Pulmonet III™, Gould, Cleveland,
OH, USA or Easyone™, NDD Medizintechnik, Zurich,
Switzerland) with flow-volume loop were performed on
patients, accordingly to the orders of the physicians in
charge. Patients performed at least three expiratory
maneuvers, with a forceful and maximal effort, in order to
obtain the best forced vital capacity (FVC) and expiratory
flow/volume loop [17]. The following indices were meas-
ured: FVC (L), FVC (percentage of predicted), forced expir-
atory volume in one second (FEV1) (L), FEV1 (percentage
of predicted), FEV1/FVC ratio (%), and forced midexpira-
tory flow rate (FEF25–75%) (percentage of predicted). Since
measurement of lung volumes by pletysmography was
rarely ordered by physicians in charge and subsequently
performed, we did not report the results.
Confirmation of congestive heart failure and COPD
The complete medical chart was reviewed, especially not-
ing medications including loop diuretics, nitrate, bron-
chodilatators and other treatments. Response to diuretic
or vasodilator, results of echocardiography-Doppler, or
BNP and NT-proBNP levels [4,18] when available were
specifically analyzed for the confirmation of CHF, by
experts (two independent senior physicians specializing
in either respirology, cardiology, internal medicine, inten-
sive care, geriatrics or emergency medicine) [1,3,18-20].
Thereafter, patients with CHF as defined by experts were
separated in two groups: patients with wheezing reportedBMC Cardiovascular Disorders 2007, 7:16 http://www.biomedcentral.com/1471-2261/7/16
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by the attending physician in the emergency room at
admission were included in the cardiac asthma group and
patients without wheezing were included in the classical
CPE group.
The diagnosis of COPD was made by experts according to
reports from a general practioner, respirologist or medical
chart from previous admission; patients' current symp-
toms (chronic cough and sputum production), clinical
findings (including clinical signs of distension); and radi-
ographic findings (Chest X-ray or CT scan) of thoracic dis-
tension [21,22]. On the chest X-ray, thoracic distension
was defined by the presence of one of the following radi-
ological signs: enlargement of intercostal space, horizon-
talization of the ribs, or flat diaphragm. Patients with
history of chronic bronchitis and signs of emphysema but
without PFT were also included in the COPD group [22].
Outcome measures
To determine the rate of readmission and long term sur-
vival, all patients were followed-up by a phone call three
months and one year after discharge.
Primary data analysis
Data are expressed as mean ± standard deviation (SD) or
median (and interquartile 25–75%) for non-Gaussian
variables. Comparison of two means was performed using
the Student's t test, comparison of two medians using the
Mann and Whitney test, and comparison of two propor-
tions using the Fisher's exact method. A multivariable
analysis was performed in order to assess predictors of car-
diac asthma. We used a conservative approach and
included in this test only variables with a p value <0.10 in
the univariate analysis. All statistical comparisons were
two-tailed and a p value of less than 0.05 was required to
reject the null hypothesis. Statistical analysis was per-
formed using computer NCSS 6.0 software (Statistical
Solutions Ltd, Cork, Ireland).
Results
Five hundred and fourteen patients were included, of
which 212 patients had a final diagnosis of CHF [5]. From
these, 75 (35%) presented with cardiac asthma, and 137
patients (65%) without wheezing had classical CPE. Table
1 compared the main characteristics of patients with CHF,
of whom 135 (64%) were aged 80 years and above.
Patients with cardiac asthma had a higher frequency of
tobacco use and diagnosis of COPD. They presented with
hypercapnic acidemia on blood gas analysis. The rate of
suspicion of CHF by emergency physician was similar in
both groups (83% in classical CPE versus 83% in the car-
diac asthma group, non significant (NS)). Treatments in
the emergency room were significantly different in the
two groups with higher prescription of bronchodilators in
the group of cardiac asthma. The chest X-ray showed tho-
racic distension more frequently in the cardiac asthma
group (16% vs. 6%, p < 0.05), but less cardiomegaly (57%
vs. 77%, p < 0.05).
The triggers of acute CHF were similar in the classical CPE
group as compared to the cardiac asthma group: systolic
arterial hypertension (26% vs. 37%, NS), myocardial
ischemia (21% vs. 15%, NS), acute pneumonia (19% vs.
16%, NS), tachyarrhythmia (17% vs. 13%, NS), anemia
(10% vs. 8%, NS).
Doppler-echocardiography was performed in 152 (72%)
patients during the hospitalization. The rate of non systo-
lic heart failure was similar in both groups (33% vs 41 %,
NS). The median (interquartile 25–75%) BNP (n = 130)
and NT-proBNP (n = 106) levels were similar in the car-
diac asthma group as compared to that of classical CPE,
576 pg/mL (247–1,080) versus 615 pg/mL (275–1,050)
and 4747 (1,164–20,458) versus 3921 pg/mL (1,788–
8,603) respectively.
All patients were hospitalized. The in-hospital mortality
was 22 %, and the rate of re-admission at three months
was 42%. The one year mortality was 54 %. The prognosis
of the two groups was similar (Fig. 1). The median length
of stays was 11 (7–16) days in the cardiac asthma group
versus 12 (7–21) days in the classical CPE group (NS). In
a multivariate analysis, the only variable available in the
ED significantly associated with cardiac asthma was a pre-
vious history of COPD, with an odds ratio of 3.26 [95%
confident interval: 1.61–6.58].
Pulmonary function tests were performed in 67 patients,
and the mean time from admission to PFTs was 6 days. In
the two groups, PFTs suggested a restrictive ventilatory
defect (normal FEV1/FVC ratio). Cardiac asthma patients
experienced obstructive airflow disorders in smaller distal
airways (table 2).
Discussion
In our study, cardiac asthma represented one third of CHF
in elderly patients. Despite a higher percentage of hyper-
capnic acidosis in the cardiac asthma group, patients pre-
sented similar short and long term prognoses. Cardiac
asthma patients exhibited greater peripheral airflow
obstruction as shown by the reduced forced expiratory
flow-rates at low lung volumes (Table 2)
Multiple studies have investigated the effects of CHF on
lung mechanics. Patients with chronic CHF and orthop-
nea have a considerable increase in airflow resistance
upon adopting the supine posture associated with supine
expiratory flow limitation [22,23]. Patients with chronic,
predominantly nonvalvular CHF frequently exhibit a
restrictive ventilatory defect, due to enlarged heart size,BMC Cardiovascular Disorders 2007, 7:16 http://www.biomedcentral.com/1471-2261/7/16
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increased intrathoracic fluids, and impaired inspiratory
muscle strength [23]. While a restrictive defect may be
seen in patients with both chronic heart failure (HF) and
acute CHF, significant airflow obstruction is more likely
to occur in the latter. Airway obstruction can occur during
CHF through various mechanisms and with various
degrees of severity [11-13,23-25]. Indeed, CHF can mimic
acute asthma, a circumstance commonly referred to as
"cardiac asthma." Pulmonary function studies have dem-
onstrated increased airway resistance or decreased forced
expiratory flows in CHF. The existence of dysfunction in
small airways in CHF is suggested by an increased closing
Table 1: Main Characteristics of Patients with Cardiac Asthma and Classical CPE
Characteristics Classical CPE Cardiac asthma
N = 137 N = 75
Demographic data
Age (years) 82 ± 9 83 ± 8
Male 62 (45%) 40 (53%)
Past medical history
Tobacco user > 20 pack/year 47 (34%) 44 (59%)*
Diabetes mellitus 32 (23%) 17 (23%)
Hypertension 125 (91%) 62 (83%)
COPD 22 (16%) 35 (47%)*
Asthma 8 (6%) 6 (8%)
Venous thrombo-embolic disease 7 (5%) 7 (9%)
Heart failure 57 (42%) 27 (36%)
Ischemic cardiac disease 57 (42%) 34 (45%)
Peripheral arterial disease 14 (10%) 18 (24%)*
Cerebrovascular disease 21 (15%) 14 (19%)
Previous medications
Beta-blockers 27 (20 %) 17 (23%)
Diuretics 86 (63%) 48 (64%)
Nitrates 63 (46%) 24 (32%)
ACE inhibitors 64 (47%) 27 (36%)
Inhaled bronchodilators 19 (14%) 36 (48%)*
Home oxygen 3 (2%) 12 (16%)*
Symptoms and physical exam at admission
Heart rate (/min) 93 ± 21 93 ± 21
Ventilatory rate (/min) 29 ± 6 29 ± 6
Systolic arterial pressure (mmHg) 144 ± 32 155 ± 30
Diastolic arterial pressure (mmHg) 78 ± 18 82 ± 20
Clinical signs of acute ventilatory failure 116 (85%) 58 (78%)
Crackles with pulmonary auscultation 121 (88%) 52 (69%)*
Signs of RV failure 93 (68%) 45 (60%)
Arterial blood gas
pH 7.43 ± 0.06 7.38 ± 0.08*
pH < 7.35 11 (8%) 20 (27%)*
PaCO2 (mmHg) 41 ± 11 47 ± 15*
PaCO2 ≥ 45 mmHg 31 (23%) 32 (42%)*
PaO2 (mmHg) 67 ± 25 67 ± 18
Bicarbonates (mmol/L) 26 ± 5 27 ± 6
Biological analysis
Creatinine clearance (mL/min) 40 (30–58) 44 (31–57)
Treatments received in the emergency room
Oxygen 133 (97%) 74 (99%)
Diuretics 89 (65%) 52 (69%)
Vasodilators 26 (19%) 19 (25%)
Nebulized β2-Agonist 1 (1%) 29 (39%)*
Nebulized Ipratropium Bromide 4 (3%) 19 (25%)*
Data are mean ± SD, median [interquartile 25–75%], or number of patients (percentage) or extremes. CPE: cardiogenic pulmonary edema; COPD: 
chronic obstructive pulmonary disease. ACE inhibitors denotes angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers; RV: 
right ventricular signs including jugular venous pressure or abdominal jugular reflux or lower-extremity edema; signs of acute ventilatory failure 
included: orthopnea, abdominal respiration, use of accessory muscles; PaO2: partial oxygen pressure; SaO2: arterial oxygen saturation; PaCO2: 
partial carbon dioxide pressure; SpO2: peripheral oxygen saturation; Creatinine clearance was estimated using the Cockcroft formula; nebulized β2-
agonists included terbutaline or salbutamol administration. *p < 0.05.BMC Cardiovascular Disorders 2007, 7:16 http://www.biomedcentral.com/1471-2261/7/16
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volume. Studies have suggested that with severe left HF
there was a significant narrowing of the large airways.
Finally, some patients with HF, when challenged with
methacholine, exhibit nonspecific bronchial hyperre-
sponsiveness. However, the majority of these studies did
not clearly distinguish smokers from nonsmokers, a his-
tory of thoracic surgery, or significant obesity. Obstructive
changes tend to be mild and appear to be more prevalent
during periods of acute decompensation of CHF. They
tend to improve with diuresis presumably due to a reduc-
tion in extravascular lung water, and a general reduction
in pulmonary and bronchial blood volumes [24]. There
also may be an enhanced degree of airway reactivity that
diminishes with diuresis. Small improvements in expira-
tory flows are observed with anticholinergic and β2-ago-
nist drugs in patients with chronic heart failure. Thus, data
about the best treatments for cardiac asthma (i.e. are
bronchodilators useful ?) are still lacking [16,26-30].
Wheezing is a frequent physical examination abnormal-
ity, common with acute asthma, exacerbation of COPD,
and cardiac asthma. In the latter, wheezing is integrated in
the Boston criteria for CHF, a clinicoradiographic vali-
dated score [20]. The prevalence of cardiac asthma has not
been specifically reported in studies of heart failure. Nev-
ertheless, recent studies found the rate of wheezing to be
10-15% in non-elderly patients with HF [2,6,31,32]. We
demonstrated a high rate of cardiac asthma (35%) in eld-
erly patients. Our study suggests that emergency physi-
cians should focus on past diagnosis of COPD in patients
with CHF and cardiac asthma, especially in those present-
ing with hypercapnia.
The population in our study of acute heart failure in eld-
erly patients seems similar to previous studies in term of
past medial history and prognosis. The in-hospital mor-
tality was 22 %, compared to a mortality ranging from
13% to 29 % in other studies [2-8]. The rate of admission
at 3 months was 42% close to a rate of early rehospitaliza-
tion from 29 to 47%, within 3 to 6 months of the initial
discharge [1,7,8]. Both groups had a similar prognosis
(Fig. 1). Indeed, one could assume that cardiac asthma
had a better prognosis because auscultation revealed
fewer crackles, which could suggest less alveolar edema
[23]. However, patients with cardiac asthma had higher
hypercapnic acidemia which is thought to be associated
with worse prognosis [7]. In fact, the usual variables for
assessing severity (respiratory rate, PaO2, median values
of BNP, rate of non systolic heart failure) confirmed sim-
ilar severity of CHF in both groups.
The method used in our study to diagnose CHF and
COPD requires further comment. For the diagnosis of
CHF there is no ideal standard. Thus, as in several previ-
ous studies, we used consensus diagnosis by experts to
assess the final diagnosis of CHF supported with results of
Doppler-echocardiography when available during hospi-
talization [3], and BNP and NT-proBNP levels performed
Immediate and Long Term Prognosis in Either Group Figure 1














% Cardiac asthma (n=75)
Classical CHF (n=137)
Table 2: Comparison of lung function parameters according to clinical presentation.
Classical CPE Cardiac asthma
N = 41 N = 26
FVC (L) 1.77 ± 0.56 1.60 ± 0.73
FVC (% predicted) 67 ± 24 65 ± 26
FEV1(L) 1.33 ± 0,5 1.09 ± 0,49*
FEV1(% predicted) 65 ± 23 58 ± 27
FEV1/FVC ratio (%) 71.2 ± 15.6 66.9 ± 14
FEV1/FVC (% predicted) 96 ± 21 90 ± 21
PEF (L/min) 172 (119 – 238) 146 (100 – 206)
PEF (% predicted) 47 (31 – 64) 40 (30 – 55)
FEF25–75 (L/s) 0.99 (0.68–1.77) 0.76 (0.38–1.10)*
FEF25–75 (% predicted) 48 (24–73) 32 (18–51)*
Data are mean ± SD, median (interquartile 25–75%); FVC: forced vital capacity, FEV: Forced Expiratory Volume In 1 Second, FEF25–75: forced 
expiratory flow at 25% to 75% of vital capacity; PEF rate: peak expiratory flow; *p < 0.05.BMC Cardiovascular Disorders 2007, 7:16 http://www.biomedcentral.com/1471-2261/7/16
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blindly at admission in the emergency room when availa-
ble [18]. As in most ED, Doppler-echocardiography was
not immediately available. It was performed in 72% of
elderly patients in our institution, and PFTs were per-
formed in 67 (32%) patients, with a mean time from
admission to PFT of 6 days. These investigations could not
been obtained in all patients, and we could not report
lung volumes measured by pletysmography.
Limitations of our study
Usually, COPD is usually defined by spirometry: i.e. pres-
ence of a FEV1/FVC<70% [21,22]. In our study, we used a
more clinical approach to assess previous medical history
of COPD, including symptoms, clinical and radiographic
results. Unfortunately, previous spirometry was not avail-
able and not reported in our study [9]. The FEV1/FVC%
was almost normal in the cardiac asthma group, and we
hypothesis that our COPD group included patients with
chronic bronchitis or emphysema and mild COPD rather
than severe COPD [22].
The only criteria listed for "cardiac asthma" was wheezing
reported by the physician's exam in the ED. There was no
objective criteria given to differentiate this from co-exist-
ing lung disease and could lead to misclassification of
CHF as being the primary event. However, the inclusion
of the NT-proBNP and BNP data soundly confirms that
this was a comparison of two cohorts with CHF (i.e. the
wheezing group indeed did have CHF as reflected by the
similar levels of BNP and NT-prBNP). At the time of the
study, we were aware that patients with CHF were under-
treated (especially with nitrates) because only two thirds
of patients in both groups received either diuretics or
nitrates [3].
Since the method used to evaluate expiratory flow limita-
tion in our study is questionable, we suggest that obstruc-
tive pattern has been underestimated [30,33]. This is
supported by a recent study which suggested that the neg-
ative expiratory pressure method was independent of
FEV1/FVC % the usual index of overt obstruction in most
groups of elderly subjects. Furthermore, some elderly
patient, mainly female, suffering from dyspnea without
medical history or decrease in FEV1/FVC %, appeared to
be more flow limited during tidal expiration than those.
Unfortunately, negative expiratory pressure method is not
associated with routine PFTs in our institution.
Measurement of lung volumes by pletysmography was
rarely performed, therefore we did not report the results of
lung volumes measurement (total lung capacity). Thus,
we can only suggest, and not strongly confirm that a
restrictive defect was present in patients with CHF.
In our study, PFTs were performed according to physi-
cians' orders, because the routine care of the patient was
not modified. The percentages of patients who had PFT
were quite similar in those with (35%) and without
(30%) wheezing at the admission, thus we do not think
that it could have biased the results. However, we agree
that some hypothesis or conclusions are based upon a
small number of patients who had PFTs (only one third).
Due to the methodology of this observational study, we
did not demonstrate that cardiac asthma was formally
associated with distal airway obstruction. The limited
sample size of our population precluded us to perform a
case control study to confirm this hypothesis.
There was a low prevalence of bronchodilators given to
the wheezing patients. This is attributed to the fact that the
medical care was decided by the physicians in charge, and
that bronchodilators have not been demonstrated to to be
surely effective in cardiac asthma [16,26-29]. Although,
bronchodilators were given in only one third of patients
with wheezing in the emergency room, patients with car-
diac asthma still had peripheral airway obstruction, sug-
gesting a more marked airflow reduction if PFTs had been
performed at admission to the emergency room. However
for ethical reasons, PFTs were not performed at admission
in the emergency room. The PFTs could have been modi-
fied if the medical care of patient had varied, especially
prescription of bronchodilators or larger doses of diuret-
ics. Thus, our results can not be extrapoled to the earlier
stage of exacerbation of CHF.
Conclusion
Cardiac asthma defined as CHF associated with wheezing
represents one third of CHF in elderly patients. Cardiac
asthma patients were more hypercapnic and had greater
peripheral airway obstruction. However, in these patients
short and long term outcomes were not dissimilar from
those of patients with classical CPE.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
PR conceived of and designed the study, performed anal-
ysis and interpretation of data, edited the manuscript, and
gave final approval of the manuscript. SJ performed inter-
pretation of data, drafted the manuscript, and gave final
approval of the manuscript. SD, MHB performed analysis
and interpretation of data and gave final approval of the
manuscript. RA, BR, RI and MB revised the manuscript
critically for important intellectual content, and gave final
approval of the manuscript.BMC Cardiovascular Disorders 2007, 7:16 http://www.biomedcentral.com/1471-2261/7/16
Page 7 of 8
(page number not for citation purposes)
Acknowledgements
We acknowledge the assistance of the other staff physicians: J-P Bouchon, 
P Hausfater, M-O Josse, B Madonna-Py, F Mazière, M Bendahou (Depart-
ment of Emergency Medicine and Surgery), all of whom work at the Pitie-
Salpêtrière Hospital, Paris, France.
References
1. Rich MW: Heart failure in the 21st century: a cardiogeriatric
syndrome.  J Gerontol A Biol Sci Med Sci 2001, 56(2):M88-96.
2. Lien CT, Gillespie ND, Struthers AD, McMurdo ME: Heart failure
in frail elderly patients: diagnostic difficulties, co-morbidi-
ties, polypharmacy and treatment dilemmas.  Eur J Heart Fail
2002, 4(1):91-98.
3. Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, Jondeau
G, Hasin Y, Lopez-Sendon J, Mebazaa A, Metra M, Rhodes A, Swed-
berg K, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie MR, Dean V,
Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, Morais J, Oto
A, Smiseth OA, Garcia MA, Dickstein K, Albuquerque A, Conthe P,
et al.: Executive summary of the guidelines on the diagnosis
and treatment of acute heart failure: the Task Force on
Acute Heart Failure of the European Society of Cardiology.
Eur Heart J 2005, 26(4):384-416.
4. Berdague P, Caffin PY, Barazer I, Vergnes C, Sedighian S, Letrillard S,
Pilossof R, Goutorbe F, Piot C, Reny JL: Use of N-terminal pro-
hormone brain natriuretic peptide assay for etiologic diag-
nosis of acute dyspnea in elderly patients.  Am Heart J 2006,
151(3):690-698.
5. Ray P, Birolleau S, Lefort Y, Becquemin MH, Beigelman C, Isnard R,
Teixeira A, Arthaud M, Riou B, Boddaert J: Acute respiratory fail-
ure in the elderly: etiology, emergency diagnosis and prog-
nosis.  Crit Care 2006, 10(3):R82.
6. Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P,
Pfisterer M, Perruchoud AP: Use of B-type natriuretic peptide in
the evaluation and management of acute dyspnea.  N Engl J
Med 2004, 350(7):647-654.
7. L'Her E, Duquesne F, Girou E, de Rosiere XD, Le Conte P, Renault S,
Allamy JP, Boles JM: Noninvasive continuous positive airway
pressure in elderly cardiogenic pulmonary edema patients.
Intensive Care Med 2004, 30(5):882-888.
8. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Car-
ney RM: A multidisciplinary intervention to prevent the
readmission of elderly patients with congestive heart failure.
N Engl J Med 1995, 333(18):1190-1195.
9. Fishman AP: Cardiac asthma – a fresh look at an old wheeze.
N Engl J Med 1989, 320(20):1346-1348.
10. Cabanes LR, Weber SN, Matran R, Regnard J, Richard MO,
Degeorges ME, Lockhart A: Bronchial hyperresponsiveness to
methacholine in patients with impaired left ventricular func-
tion.  N Engl J Med 1989, 320(20):1317-1322.
11. Nishimura Y, Maeda H, Hashimoto A, Tanaka K, Yokoyama M: Rela-
tionship between bronchial hyperreactivity and symptoms of
cardiac asthma in patients with non-valvular left ventricular
failure.  Jpn Circ J 1996, 60(12):933-939.
12. Moore DP, Weston A, Hughes JM, Oakley CM, Cleland JG: Bron-
chial hyperresponsiveness in heart failure.  N Engl J Med 1993,
328(19):1424-1425.
13. Sasaki F, Ishizaki T, Mifune J, Fujimura M, Nishioka S, Miyabo S: Bron-
chial hyperresponsiveness in patients with chronic conges-
tive heart failure.  Chest 1990, 97(3):534-538.
14. Faggiano P: Abnormalities of pulmonary function in congestive
heart failure.  Int J Cardiol 1994, 44(1):1-8.
15. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis
GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ,
Packer M, Silver MA, Stevenson LW, Gibbons RJ, Antman EM, Alpert
JS, Faxon DP, Fuster V, Jacobs AK, Hiratzka LF, Russell RO, Smith SC
Jr, American College of Cardiology/American Heart Association:
ACC/AHA guidelines for the evaluation and management of
chronic heart failure in the adult: executive summary. A
report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines (Com-
mittee to revise the 1995 Guidelines for the Evaluation and
Management of Heart Failure).  J Am Coll Cardiol 2001,
38(7):2101-2113.
16. Interiano B, Hyde RW, Hodges M, Yu PN: Interrelation between
alterations in pulmonary mechanics and hemodynamics in
acute myocardial infarction.  J Clin Invest 1973, 52(8):1994-2006.
17. Quanjer PH, Tammeling GJ, Cotes JE, O Pederson, Peslin F, Yernault
J-C: Lung volumes and forced ventilatory flows.  Eur Respir J
1993, 6(Suppl 16):5-40.
18. Ray P, Arthaud M, Birolleau S, Isnard R, Lefort Y, Boddaert J, Riou B:
Comparison of brain natriuretic peptide and probrain natri-
uretic peptide in the diagnosis of cardiogenic pulmonary
edema in patients aged 65 and older.  J Am Geriatr Soc 2005,
53(4):643-648.
19. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar
JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev
VS, Preda I, van Gilst WH, Widimsky J, Freemantle N, Eastaugh J,
Mason J, Study Group on Diagnosis of the Working Group on Heart
Failure of the European Society of Cardiology: The EuroHeart Fail-
ure survey programme – a survey on the quality of care
among patients with heart failure in Europe. Part 1: patient
characteristics and diagnosis.  Eur Heart J 2003, 24(5):442-463.
20. Arques S, Roux E, Ambrosi P, Sbragia P, Gelisse R, Pieri B, Luccioni R:
Accuracy of bedside tissue Doppler echocardiography for
the prediction of in-hospital mortality in elderly patients
with acute heart failure with preserved left ventricular systo-
lic function. Comparison with B-type natriuretic peptide
measurement.  Int J Cardiol  in press. 2007 Feb 5
21. Straus SE, McAlister FA, Sackett DL, Deeks JJ: The accuracy of
patient history, wheezing, and laryngeal measurements in
diagnosing obstructive airway disease. CARE-COAD1
Group. Clinical Assessment of the Reliability of the Examina-
tion-Chronic Obstructive Airways Disease.  JAMA 2000,
283(14):1853-7.
22. Pauwels R, Buist A, Calverley P, Jenkins C, Hurd S: Global strategy
for the diagnosis, management and prevention of chronic
obstructive pulmonary disease.  Am J Respir Crit Care Med 2001,
163(5):1256-1276.
23. Gehlbach BK, Geppert E: The pulmonary manifestations of left
heart failure.  Chest 2004, 125(2):669-682.
24. Pison C, Malo JL, Rouleau JL, Chalaoui J, Ghezzo H, Malo J: Bronchial
hyperresponsiveness to inhaled methacholine in subjects
with chronic left heart failure at a time of exacerbation and
after increasing diuretic therapy.  Chest 1989, 96(2):230-235.
25. Snashall PD, Chung KF: Airway obstruction and bronchial
hyperresponsiveness in left ventricular failure and mitral ste-
nosis.  Am Rev Respir Dis 1991, 144(4):945-956.
26. Kindman LA, Vagelos RH, Willson K, Prikazky L, Fowler M: Abnor-
malities of pulmonary function in patients with congestive
heart failure, and reversal with ipratropium bromide.  Am J
Cardiol 1994, 73(4):258-262.
27. Faggiano P, Lombardi C, Sorgato A, Ghizzoni G, Spedini C, Rusconi
C: Pulmonary function tests in patients with congestive heart
failure: effects of medical therapy.  Cardiology 1993, 83(1–
2):30-35.
28. Rolla G, Bucca C, Brussino L, Gallo W, Malara D: Bronchodilating
effect of ipratropium bromide in heart failure.  Eur Respir J
1993, 6(10):1492-1495.
29. Duguet A, Tantucci C, Lozinguez O, Isnard R, Thomas D, Zelter M,
Derenne JP, Milic-Emili J, Similowski T: Expiratory flow limitation
as a determinant of orthopnea in acute left heart failure.  J
Am Coll Cardiol 2000, 35(3):690-700.
30. de Bisschop C, Marty ML, Tessier JF, Barberger-Gateau P, Dartigues
JF, Guenard H: Expiratory flow limitation and obstruction in
the elderly.  Eur Respir J 2005, 26(4):594-601.
31. Dao Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirnovin R, Len-
ert L, Clopton P, Alberto J, Hlavin P, Maisel AS: Utility of B-type
natriuretic peptide in the diagnosis of congestive heart fail-
ure in an urgent-care setting.  J Am Coll Cardiol 2001,
37(2):379-385.
32. Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA,
Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-
Jones DM, Brown DF, Foran-Melanson S, Sluss PM, Lee-Lewan-
drowski E, Lewandrowski KB: The N-terminal Pro-BNP investi-
gation of dyspnea in the emergency department (PRIDE)
study.  Am J Cardiol 2005, 95(8):948-954.
33. Vanpee D, Delwiche JP, Swine C, Jamart J, Delaunois L: Does nega-
tive expiratory pressure (NEP) during spontaneous breath-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cardiovascular Disorders 2007, 7:16 http://www.biomedcentral.com/1471-2261/7/16
Page 8 of 8
(page number not for citation purposes)
ing predict respiratory impairment in elderly?  Respir Med
2005, 99(1):66-69.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2261/7/16/prepub